11βHSD1 Inhibition with AZD4017 Improves Lipid Profiles and Lean Muscle Mass in Idiopathic Intracranial Hypertension
暂无分享,去创建一个
K. Storbeck | G. Lavery | A. Sinclair | P. Stewart | W. Arlt | A. Taylor | J. Tomlinson | H. Botfield | S. Mollan | R. Fairclough | R. Hardy | Z. Alimajstorovic | L. Gilligan | R. Ottridge | K. Markey | C. Westgate | A. Yiangou | J. Mitchell | Michael S Sagmeister
[1] M. Cooper,et al. 11β-HSD1 plays a critical role in trabecular bone loss associated with systemic glucocorticoid therapy , 2019, Arthritis Research & Therapy.
[2] Simon W. Jones,et al. Therapeutic glucocorticoids prevent bone loss but drive muscle wasting when administered in chronic polyarthritis , 2019, Arthritis Research & Therapy.
[3] A. Sinclair,et al. Association Between Idiopathic Intracranial Hypertension and Risk of Cardiovascular Diseases in Women in the United Kingdom , 2019, JAMA neurology.
[4] N. Ives,et al. 11β-Hydroxysteroid dehydrogenase type 1 inhibition in idiopathic intracranial hypertension: a double-blind randomized controlled trial , 2019, bioRxiv.
[5] J. Gibney,et al. A unique androgen excess signature in idiopathic intracranial hypertension is linked to cerebrospinal fluid dynamics , 2019, JCI insight.
[6] E. Frew,et al. The expanding burden of idiopathic intracranial hypertension , 2018, Eye.
[7] M. Cooper,et al. 11 Beta-hydroxysteroid dehydrogenase type 1 regulates synovitis, joint destruction, and systemic bone loss in chronic polyarthritis , 2018, Journal of autoimmunity.
[8] A. Sinclair,et al. Metabolic Concepts in Idiopathic Intracranial Hypertension and Their Potential for Therapeutic Intervention , 2018, Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society.
[9] K. Digre,et al. Idiopathic intracranial hypertension: consensus guidelines on management , 2018, Journal of Neurology, Neurosurgery, and Psychiatry.
[10] N. Ives,et al. Assessing the Efficacy and Safety of an 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor (AZD4017) in the Idiopathic Intracranial Hypertension Drug Trial, IIH:DT: Clinical Methods and Design for a Phase II Randomized Controlled Trial , 2017, JMIR research protocols.
[11] K. Manolopoulos,et al. Evaluating the Fat Distribution in Idiopathic Intracranial Hypertension Using Dual-Energy X-ray Absorptiometry Scanning , 2017, Neuro-ophthalmology.
[12] D. Hainzl,et al. Oral administration of the 11β-hydroxysteroid-dehydrogenase type 1 inhibitor RO5093151 to patients with glaucoma: an adaptive, randomised, placebo-controlled clinical study , 2017, BMJ Open Ophthalmology.
[13] K. Storbeck,et al. A new dawn for androgens: Novel lessons from 11-oxygenated C19 steroids , 2017, Molecular and Cellular Endocrinology.
[14] K. Storbeck,et al. 11-Oxygenated C19 Steroids Are the Predominant Androgens in Polycystic Ovary Syndrome , 2016, The Journal of clinical endocrinology and metabolism.
[15] Simon W. Jones,et al. 11β‐Hydroxysteroid dehydrogenase type 1 within muscle protects against the adverse effects of local inflammation , 2016, The Journal of pathology.
[16] H. E. Maclean,et al. Muscle-specific androgen receptor deletion shows limited actions in myoblasts but not in myofibers in different muscles in vivo. , 2016, Journal of molecular endocrinology.
[17] A. Sinclair,et al. Evolving evidence in adult idiopathic intracranial hypertension: pathophysiology and management , 2016, Journal of Neurology, Neurosurgery & Psychiatry.
[18] K. Jeong,et al. A potent and selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, SKI2852, ameliorates metabolic syndrome in diabetic mice models. , 2015, European journal of pharmacology.
[19] J. Swales,et al. Continuous inhibition of 11β‐hydroxysteroid dehydrogenase type I in adipose tissue leads to tachyphylaxis in humans and rats but not in mice , 2015, British journal of pharmacology.
[20] Zaki K Hassan-Smith,et al. Gender-Specific Differences in Skeletal Muscle 11β-HSD1 Expression Across Healthy Aging. , 2015, The Journal of clinical endocrinology and metabolism.
[21] M. Cooper,et al. Differential glucocorticoid metabolism in patients with persistent versus resolving inflammatory arthritis , 2015, Arthritis Research & Therapy.
[22] T. Heise,et al. Safety, efficacy and weight effect of two 11β‐HSD1 inhibitors in metformin‐treated patients with type 2 diabetes , 2014, Diabetes, obesity & metabolism.
[23] G. Marek,et al. Efficacy and safety evaluation of HSD-1 inhibitor ABT-384 in Alzheimer's disease , 2014, Alzheimer's & Dementia.
[24] Zaki K Hassan-Smith,et al. 11β-HSD1 is the major regulator of the tissue-specific effects of circulating glucocorticoid excess , 2014, Proceedings of the National Academy of Sciences.
[25] N. Stefan,et al. Inhibition of 11β-HSD1 with RO5093151 for non-alcoholic fatty liver disease: a multicentre, randomised, double-blind, placebo-controlled trial. , 2014, The lancet. Diabetes & endocrinology.
[26] N. Crabtree,et al. Hyperandrogenemia Predicts Metabolic Phenotype in Polycystic Ovary Syndrome: The Utility of Serum Androstenedione , 2014, The Journal of clinical endocrinology and metabolism.
[27] J. Thissen,et al. Glucocorticoid-induced skeletal muscle atrophy. , 2013, The international journal of biochemistry & cell biology.
[28] M. Narici,et al. Sarcopenia, Dynapenia, and the Impact of Advancing Age on Human Skeletal Muscle Size and Strength; a Quantitative Review , 2012, Front. Physio..
[29] Martin J Packer,et al. Discovery of a potent, selective, and orally bioavailable acidic 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor: discovery of 2-[(3S)-1-[5-(cyclohexylcarbamoyl)-6-propylsulfanylpyridin-2-yl]-3-piperidyl]acetic acid (AZD4017). , 2012, Journal of medicinal chemistry.
[30] E. Lai,et al. Effects of an 11β‐hydroxysteroid dehydrogenase type 1 inhibitor, MK‐0916, in patients with type 2 diabetes mellitus and metabolic syndrome , 2011, Diabetes, obesity & metabolism.
[31] R. Perfetti,et al. Population Pharmacokinetic/Pharmacodynamic Model of Subcutaneous Adipose 11β‐Hydroxysteroid Dehydrogenase Type 1 (11β‐HSD1) Activity After Oral Administration of AMG 221, a Selective 11β‐HSD1 Inhibitor , 2011, Journal of clinical pharmacology.
[32] P. Feig,et al. Efficacy and safety of the selective 11β-HSD-1 inhibitors MK-0736 and MK-0916 in overweight and obese patients with hypertension. , 2011, Journal of the American Society of Hypertension : JASH.
[33] A. V. van Beek,et al. Cerebrospinal fluid corticosteroid levels and cortisol metabolism in patients with idiopathic intracranial hypertension: a link between 11beta-HSD1 and intracranial pressure regulation? , 2010, The Journal of clinical endocrinology and metabolism.
[34] C. Clarke,et al. Low energy diet and intracranial pressure in women with idiopathic intracranial hypertension: prospective cohort study , 2010, BMJ : British Medical Journal.
[35] J. Rosenstock,et al. The 11-β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor INCB13739 Improves Hyperglycemia in Patients With Type 2 Diabetes Inadequately Controlled by Metformin Monotherapy , 2010, Diabetes Care.
[36] I. Heilberg,et al. Influence of muscle mass and physical activity on serum and urinary creatinine and serum cystatin C. , 2008, Clinical journal of the American Society of Nephrology : CJASN.
[37] C. Schnackenberg. 11beta-hydroxysteroid dehydrogenase type 1 inhibitors for metabolic syndrome. , 2008, Current opinion in investigational drugs.
[38] Stephen R James,et al. Inhibition of 11βHSD1 with the S-phenylethylaminothiazolone BVT116429 increases adiponectin concentrations and improves glucose homeostasis in diabetic KKAy mice , 2008, BMC Pharmacology.
[39] R. Thieringer,et al. 11beta-HSD1 inhibition improves triglyceridemia through reduced liver VLDL secretion and partitions lipids toward oxidative tissues. , 2007, American journal of physiology. Endocrinology and metabolism.
[40] P. Murray,et al. Corticosteroids, 11β‐Hydroxysteroid Dehydrogenase Isozymes and the Rabbit Choroid Plexus , 2007, Journal of neuroendocrinology.
[41] R. Thieringer,et al. 11β-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice , 2005, The Journal of experimental medicine.
[42] P. Stewart,et al. 11β-Hydroxysteroid dehydrogenase and the pre-receptor regulation of corticosteroid hormone action , 2005 .
[43] B. Walker,et al. Increased in vivo regeneration of cortisol in adipose tissue in human obesity and effects of the 11beta-hydroxysteroid dehydrogenase type 1 inhibitor carbenoxolone. , 2005, Diabetes.
[44] Wei Zheng,et al. Androgen receptor in human skeletal muscle and cultured muscle satellite cells: up-regulation by androgen treatment. , 2004, The Journal of clinical endocrinology and metabolism.
[45] L. Abrahmsén,et al. Selective inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains. , 2003, Endocrinology.
[46] T. Olsson,et al. Tissue-specific dysregulation of cortisol metabolism in human obesity. , 2001, The Journal of clinical endocrinology and metabolism.